P00519 (ABL1_HUMAN) Homo sapiens (Human)
Tyrosine-protein kinase ABL1 UniProtKBInterProSTRINGInteractive Modelling
1130 aa; Sequence (Fasta) ; (Isoform 2)
Available Structures
84 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal structure of monobody SH13/ABL1 SH2 domain complex |
Heteromer | 100 | 1×SO4; | |||
| CRYSTAL STRUCTURE OF MONOBODY AS25/ABL1 SH2 DOMAIN COMPLEX, CRYSTAL A |
Heteromer P02751; | 100 | 1×GOL; | |||
| CRYSTAL STRUCTURE OF MONOBODY AS25/ABL1 SH2 DOMAIN COMPLEX, CRYSTAL B |
Heteromer P02751; | 100 | 5×GOL; 2×IMD; | |||
| Crystal Structure of Monobody HA4/Abl1 SH2 Domain Complex |
Heteromer | 100 | 1×PO4; | |||
| Crystal structure of monobody 7c12/abl1 sh2 domain complex |
Heteromer | 100 | 4×GOL; 1×SO4; | |||
| CRYSTAL STRUCTURE OF MONOBODY GG3/ABL1 SH2 DOMAIN COMPLEX |
Heteromer P02751; | 100 | ||||
| Crystal structure of the Abl-SH3 domain complexed with the high affinity peptide P0 |
Heteromer Q9Y3L3; | 100 | ||||
| Ternary complex of an Crk SH2 domain, Crk-derived phophopeptide, and Abl SH3 domain by NMR spectros… |
Heteromer P46108; Q64010; | 100 | ||||
| Crystal structure of the N114A mutant of the Abl-SH3 domain complexed with the high affinity peptid… |
Heteromer Q9Y3L3; | 98.21 | ||||
| C-abl Kinase domain with the activator(cmpd6), 2-cyano-N-(4-(3,4-dichlorophenyl)thiazol-2-yl)acetam… | homo-2-mer | 100.0 | 4×SO4; 2×STI; 2×KWD; 1×2PE; | |||
| C-abl Kinase domain with the activator(cmpd29), N-(1-(3,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-… | homo-2-mer | 100.0 | 2×STI; 2×KWV; 1×SO4; 2×GOL; 1×2PE; | |||
| The crystal structure of human abl1 kinase domain in complex with ABL1-A11 | homo-2-mer | 100.0 | 2×8DW; | |||
| The crystal structure of human abl1 kinase domain in complex with ABL2-A5 | homo-2-mer | 100 | 2×8IW; | |||
| Crystal structure of the N114Q mutant of ABL-SH3 domain complexed with a designed high-affinity pep… | homo-2-mer | 98.28 | 2×SO4; | |||
| Organization of the SH3-SH2 Unit in Active and Inactive Forms of the c-Abl Tyrosine Kinase | monomer | 99.78 | 1×MYR; 1×P16; 2×GOL; | |||
| Structural basis for the auto-inhibition of c-Abl tyrosine kinase | monomer | 99.78 | 1×MYR; 1×P16; | |||
| ABL1 kinase (T334I_D382N) in complex with asciminib and nilotinib | monomer | 99.53 | 1×NIL; 1×AY7; | |||
| Abl kinase in complex with SKI and asciminib | monomer | 100.0 | 1×AY7; 1×SKI; 1×CL; 2×SO4; 3×DMS; | |||
| Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinas… | monomer | 99.3 | 1×VX6; | |||
| Abl 1b isoform inactive2 state | monomer | 98.95 | ||||
| Abl isoform 1b inactive1 state | monomer | 100 | ||||
| Abl 1b isoform active state | monomer | 100 | ||||
| A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain | monomer | 99.64 | 1×112; | |||
| Crystal structure of the c-Abl kinase domain in complex with INNO-406 | monomer | 100.0 | 1×406; | |||
| A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain | monomer | 99.63 | 1×ADP; | |||
| Crystal structure of an SH2-kinase domain construct of c-Abl tyrosine kinase | monomer | 100.0 | 1×1N1; | |||
| A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain | monomer | 99.63 | 1×P16; | |||
| X-ray Crystal Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain | monomer | 100 | 1×1N1; | |||
| Crystal structure of ABL1 in complex with CHMFL-074 | monomer | 100.0 | 2×66K; 12×EDO; 1×CL; | |||
| A Src-like Inactive Conformation in the Abl Tyrosine Kinase Domain | monomer | 100 | 1×MG; 1×112; | |||
| The crystal structure of human abl1 T315I gatekeeper mutant kinase domain in complex with axitinib | monomer | 99.62 | 1×AXI; 2×NI; 2×NA; | |||
| Crystal structure of the T315I Abl mutant in complex with the inhibitor PHA-739358 | monomer | 99.63 | 1×627; 1×MG; | |||
| The crystal structure of human abl1 kinase domain in complex with DCC-2036 | monomer | 100 | 2×NA; 1×919; | |||
| Crystal Structure of Inactive Conformation Abl Kinase Catalytic Domain Complexed with Type II Inhib… | monomer | 100 | 1×7MP; | |||
| Structural and spectroscopic analysis of the kinase inhibitor bosutinib binding to the Abl tyrosine… | monomer | 100 | 1×DB8; | |||
| Predicting the Conformational Variability of Abl Tyrosine Kinase Using Molecular Dynamics Simulatio… | monomer | 98.89 | 1×PVB; 1×SO4; | |||
| Discovery and Characterization of a Cell-Permeable, Small-molecule c-Abl Kinase Activator that Bind… | monomer | 100.0 | 2×SO4; 1×STI; 1×3YY; | |||
| C-abl Kinase domain with the activator(cmpd51), N-(1-(3,4-dichlorophenyl)-4-(2-hydroxyethyl)-4,5-di… | monomer | 100.0 | 1×SO4; 1×STI; 1×KWP; | |||
| The crystal structure of human abl1 kinase domain in complex with ABL1-B1 | monomer | 100.0 | 1×6CI; | |||
| The crystal structure of human abl1 kinase domain in complex with abl1-A-EBA | monomer | 100 | 1×QH9; | |||
| VX-680/MK-0457 binds to human ABL1 also in inactive DFG conformations. | monomer | 100 | 1×VX6; 3×MXE; | |||
| The crystal structure of human abl1 kinase domain in complex with abl1-B-EBA | monomer | 100.0 | 1×QEW; | |||
| Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL Inhibitors | monomer | 100.0 | 1×FVC; | |||
| The crystal structure of human abl1 kinase domain in complex with ABL1-B4 | monomer | 100.0 | 1×6I5; | |||
| C-Helix-Out Binding of Dasatinib Analog to c-Abl Kinase | monomer | 100.0 | 1×4B7; 1×EDO; 1×MES; | |||
| Abl kinase domain in complex with PD180970 | monomer | 100 | 1×JIN; | |||
| Human ABL kinase in complex with nilotinib | monomer | 100.0 | 1×NIL; | |||
| The crystal structure of human abl1 kinase domain in complex with ABL1-B5 | monomer | 100.0 | 1×6CI; 1×BAL; | |||
| The crystal structure of human abl1 kinase domain in complex with DP-987 | monomer | 100 | 1×9DP; | |||
| Strategic design of catalytic lysine-targeting reversible covalent BCR-ABL Inhibitors | monomer | 100.0 | 1×HJ9; | |||
| Abl kinase domain unligated and in complex with tetrahydrostaurosporine | monomer | 100.0 | 1×4ST; | |||
| Crystal structure of the Abl 1b Kinase domain in complex with Dasatinib and Imatinib | monomer | 100.0 | 1×STI; 1×1N1; 1×PO4; | |||
| Abl kinase domain in complex with NVP-AEG082 | monomer | 100 | 1×GIN; | |||
| Human Abl kinase domain in complex with imatinib (STI571, Glivec) | monomer | 100.0 | 1×STI; | |||
| The crystal structure of human abl1 kinase domain T315I mutant in complex with DCC-2036 | monomer | 99.61 | 1×919; | |||
| The crystal structure of human abl1 wild type kinase domain in complex with axitinib | monomer | 100 | 1×AXI; | |||
| Abl1b Regulatory Module 'Activating' conformation | monomer | 92.21 | ||||
| Abl 1b Regulatory Module 'inhibiting state | monomer | 92.21 | ||||
| SH3-SH2 DOMAIN FRAGMENT OF HUMAN BCR-ABL TYROSINE KINASE | monomer | 100 | ||||
| Solution structure of the F-actin binding domain of Bcr-Abl/c-Abl | monomer | 99.06 | ||||
| THREE-DIMENSIONAL SOLUTION STRUCTURE OF THE SRC HOMOLOGY 2 DOMAIN OF C-ABL | monomer | 100 | ||||
| Crystal structure of the N114A mutant of ABL-SH3 domain | monomer | 98.39 | 1×GOL; | |||
| Crystal structure of the N114A Abl-SH3 domain mutant at pH4 | monomer | 98.28 | 1×PEG; 2×NA; | |||
| Crystal structure of the N114Q mutant of ABL-SH3 domain | monomer | 98.39 | 1×GOL; | |||
| Crystal structure of the Abl-SH3 domain at pH 7.5 | monomer | 100 | 1×PEG; | |||
| Crystal structure of the ABL-SH3 domain complexed with the designed high-affinity peptide ligand P7… | monomer | 100 | ||||
| Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in pres… | monomer | 84.48 | 1×PGE; 1×NA; 3×SO4; | |||
| Crystal structure of the Abl-SH3 domain H59Q-N96T mutant complexed with the designed high-affinity … | monomer | 96.55 | 1×PGE; 1×PEG; | |||
| Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in the … | monomer | 84.48 | ||||
| Crystal structure of the Abl-SH3 domain at pH5 | monomer | 100 | 1×PEG; | |||
| Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E-G92N-Y93N-N94T-H95E mutant in the … | monomer | 84.48 | ||||
| CRYSTAL STRUCTURE OF THE ABL-SH3 DOMAIN COMPLEXED WITH A DESIGNED HIGH-AFFINITY PEPTIDE LIGAND: IMP… | monomer | 100 | 1×SO4; | |||
| Crystal structure of the Abl-SH3 domain H59Q-N96T mutant | monomer | 96.55 | 2×PEG; | |||
| Crystal structure of the N114A mutant of ABL-SH3 domain complexed with a designed high-affinity pep… | monomer | 98.28 | 1×SO4; | |||
| Crystal structure of the ABL-SH3 domain complexed with the designed high-affinity peptide ligand P7… | monomer | 100 | ||||
| Crystal structure of the Abl SH3 domain V73E-A74S-S75R-G76T-D77E mutant | monomer | 91.23 | ||||
| Crystal structure of the Abl-SH3 domain at pH3 | monomer | 100 | 2×PEG; 1×SO4; | |||
| Crystal structure of the Abl SH3 domain G92N-Y93N-N94T-H95E mutant | monomer | 92.98 | 1×PEG; 1×PGE; | |||
| Crystal structure of the N114A mutant of ABL-SH3 domain | monomer | 98.25 | 1×SO4; 1×GOL; | |||
| THE SOLUTION NMR STRUCTURE OF ABL SH3 AND ITS RELATIONSHIP TO SH2 IN THE SH(32) CONSTRUCT, 20 STRUC… | monomer | 96.49 | ||||
| Crystal structure of the N114A mutant of the Abl-SH3 domain complexed with the high affinity peptid… | monomer | 98.21 | ||||
| Abl1 SH3 pTyr89/134 | monomer | 100 | ||||
| Crystal structure of the ABL-SH3 domain complexed with the designed high-affinity peptide ligand P17 | monomer | 100 | ||||
| Crystal structure of the N114T mutant of ABL-SH3 domain | monomer | 98.21 | 1×GOL; | |||
4 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 1opl.1.A | monomer | 0.81 | 1×MYR; 1×P16; | 99.39 | ||
| 1opl.2.A | monomer | 0.78 | 1×P16; | 99.39 | ||
| 1zzp.1.A | monomer | 0.77 | 99.19 | |||
| 1y57.1.A | monomer | 0.69 | 43.06 | |||
4 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 1opl.1.A | monomer | 0.81 | 1×MYR; 1×P16; | 99.44 | ||
| Isoform 2 | 1opl.2.A | monomer | 0.78 | 1×P16; | 99.44 | ||
| Isoform 2 | 1zzp.1.A | monomer | 0.77 | 99.19 | |||
| Isoform 2 | 1y57.1.A | monomer | 0.69 | 43.06 | |||